Business
ONWARD Medical Reports Full Year 2025 Financial and Operating Results, Highlighting Strong US Commercial Performance and Major Pipeline Milestones
THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE 7(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014) EINDHOVEN, the Netherlands, March 31, 2026 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD – US ADR: ONWRY), the leading neurotechnology company pioneering therapies to restore movement, function, and independence in people with spinal cord injuries (SCI) and other movement disabilities, today announces its financial and operating results for the full year
About this update from Onward Medical N.v.
[{"type":"image","alt":"ONWARD Medical NV","displaySize":"","headline":null,"caption":"ONWARD Medical NV","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":150,"url":"https://media.zenfs.com/en/globenewswire.com/ff435d5a4437f6b633ad80dab68096d0"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/k5H42ENtwWiIFVl5nWlEJQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIxMA--/https://media.zenfs.com/en/globenewswire.com/ff435d5a4437f6b633ad80dab68096d0","width":300,"height":150}},"lazy":false},{"type":"text","content":"THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE 7(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014)","length":132,"tagName":"p"},{"type":"text","content":"EINDHOVEN, the Netherlands, March 31, 2026 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD – US ADR: ONWRY), the leading neurotechnology company pioneering therapies to restore movement, function, and independence in people with spinal cord injuries (SCI) and other movement disabilities, today announces its financial and operating results for the full year 2025:","length":377,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Commercial traction: The Company initiated the commercialization of its first technology platform and sold 117 ARC-EX® Systems, demonstrating strong commercial traction for its groundbreaking external spinal stimulation system. ARC-EX was sold to more than 80 US rehabilitation clinics by the end of the year.","length":309,"tagName":"p"}]},{"val":[{"type":"text","content":"Regulatory milestones: The Company received CE Mark certification for the ARC-EX System for use in both clinics and homes. In November, the US Food and Drug Administration (FDA) granted 510(k) clearance to expand the ARC-EX System indication for home use in the US. Additionally, the FDA approved an investigational device exemption (IDE) for the ARC-IM® System, allowing the initiation of the Empower BP global pivotal study.","length":426,"tagName":"p"}]},{"val":[{"type":"text","content":"Science & technology leadership: The Company announced the simultaneous publications of two articles in Nature and Nature Medicine, further expanding the body of scientific and clinical evidence supporting ARC-IM Therapy. Additional publications in Neuromodulation: Technology at the Neural Interface and Neurology: Clinical Pra...